In the future, perhaps 20 years from now, cannabis-based medicines will have a prominent place in the worldwide pharmacopeia again. Indeed, we might have even gotten there much faster if it hadn’t been for the draconian interference of the U.S. government. To this day, they are still blocking researchers from accessing cannabis to study.
Countless thousands have died suffering and millions more continue to be denied access to plant-based medications that could not only mitigate their misery, but also possibly even cure them.Cannabis medications work so efficiently because of the endocannabinoid (EC) system, present in all humans and many animals as well. This system consists of a series of receptors that are configured only to accept cannabinoids, especially tetrahydrocannabinol (THC) and cannabidiol (CBD).
Not enough research has been done on the other ones, cannabinol (CBN) and cannabigerol (CBG) plus others, to know much about their mechanisms of effect.This system, an integral part of our physiologies, was discovered in the mid-1990s by Israeli researcher Dr. Ralph Mechoulam who also identified THC as the main active ingredient in cannabis in the early 1960s.
Israel has been one of the most progressive nations for cannabis research and currently has one of the most advanced medical marijuana programs in the world. They are international leaders in advanced greenhouse technology, routinely producing flowers with 20 percent or greater THC.Dr. Mechoulam’s world-changing research discovered two main receptors, cannabinoid 1 (CB1) and cannabinoid 2 (CB2), that are keyed to both the endocannabinoids that our body naturally produces and phytocannabinoids (plant-based) like THC and CBD.
Our bodies actually produce the ECs similar to how our body produces narcotic-like endorphins. Synthetic cannabinoids, like the ones found in Marinol, also fit the receptor sites but don’t work as efficiently as the natural ones.
READ THE FULL STORY BELOW